NASDAQ:BNTX BioNTech (BNTX) Stock Price, News & Analysis $80.77 -0.61 (-0.75%) Closing price 11/20/2026 03:58 PM EasternExtended Trading$81.50 +0.73 (+0.90%) As of 11/20/2026 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About BioNTech Stock (NASDAQ:BNTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BioNTech alerts:Sign Up Key Stats Today's Range$80.27▼$82.8750-Day Range$80.77▼$100.8752-Week Range$79.52▼$124.00Volume1.71 million shsAverage Volume997,830 shsMarket Capitalization$20.43 billionP/E RatioN/ADividend YieldN/APrice Target$120.44Consensus RatingModerate Buy Company Overview BioNTech SE is a biotechnology company based in Mainz, Germany. Founded in 2008, it develops medicines and vaccines, with a focus on immunotherapies for cancer and infectious diseases. The company’s research uses technologies including messenger RNA (mRNA), antibodies, and cell-based therapies. Its best-known product is Comirnaty, an mRNA vaccine against COVID-19 developed and commercialized in partnership with Pfizer. BioNTech also has a broad oncology research and development portfolio. BioNTech works with partners to develop and distribute products internationally. It was co-founded by Ugur Sahin and Özlem Türeci; Sahin has served as the company’s chief executive officer.AI Generated. May Contain Errors. Read More BioNTech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreBNTX MarketRank™: 3.65063788027 of 5 starsBioNTech scored higher than 73% of companies evaluated by MarketBeat, and ranked 157th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingBioNTech has received a consensus rating of Moderate Buy. The company's average rating score is 2.65, and is based on 1 strong buy rating, 12 buy ratings, 6 hold ratings, and 1 sell rating.Upside PotentialBioNTech has a consensus price target of $120.44, representing about 49.1% upside from its current price of $80.77.Amount of Analyst CoverageBioNTech has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BioNTech's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BioNTech are expected to grow in the coming year, from ($6.38) to ($5.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioNTech is -11.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioNTech is -11.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioNTech has a P/B Ratio of 1.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.10% of the float of BioNTech has been sold short.Short Interest Ratio / Days to CoverBioNTech has a short interest ratio ("days to cover") of 2.15, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioNTech has recently decreased by 1.17%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldBioNTech does not currently pay a dividend.Dividend GrowthBioNTech does not have a long track record of dividend growth.Read more about BioNTech's dividend. News and Social Media2.5 / 5News Sentiment0.99 News SentimentBioNTech has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for BioNTech this week, compared to 8 articles on an average week.Search InterestOnly 4 people have searched for BNTX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added BioNTech to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, BioNTech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $79,246,837.00 in company stock.Percentage Held by Insiders19.20% of the stock of BioNTech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions15.52% of the stock of BioNTech is held by institutions.Read more about BioNTech's insider trading history. Receive BNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BNTX Stock News HeadlinesBioNTech SE Sponsored ADR (NASDAQ:BNTX) Stock Rated "Moderate Buy" by Wall Street AnalystsNovember 22 at 3:00 AM | americanbankingnews.comJPMorgan Chase & Co. Forecasts Strong Price Appreciation for BioNTech (NASDAQ:BNTX) StockNovember 21 at 2:18 AM | americanbankingnews.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.November 22 at 1:00 AM | Profits Run (Ad)Analysts Conflicted on These Healthcare Names: CSPC Pharmaceutical Group (OtherCHJTF) and BioNTech SE (BNTX)November 20 at 8:24 AM | theglobeandmail.comModerna vs. BioNTech: Why Only 1 Is a Buy Heading Into 2027November 20 at 3:55 AM | fool.comBioNTech: Priority Review Voucher Purchase Hints At Much Needed Approval ShotNovember 18, 2026 | seekingalpha.comBioNTech (BNTX) Dropped, So What Is Driving Attention Now?November 13, 2026 | finance.yahoo.comBioNTech May Be the Next Moderna. Even if it Isn't, the Stock Is a Buy.November 12, 2026 | barrons.comSee More Headlines BNTX Stock Analysis - Frequently Asked Questions How have BNTX shares performed this year? BioNTech's stock was trading at $95.20 on January 1st, 2026. Since then, BNTX stock has decreased by 15.2% and is now trading at $80.7730. How were BioNTech's earnings last quarter? BioNTech SE Sponsored ADR (NASDAQ:BNTX) issued its quarterly earnings results on Tuesday, August, 4th. The company reported ($2.53) earnings per share for the quarter, missing analysts' consensus estimates of ($2.40) by $0.14. The company's revenue was down 59.5% compared to the same quarter last year. Read the conference call transcript. How will BioNTech's stock buyback program work? BioNTech's board initiated a share buyback plan on Thursday, May 7th 2026, which permits the company to repurchase $1 billion in outstanding shares, according to EventVestor. This means that the company could reacquire up to 4.2% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's leadership believes its shares are undervalued. Does BioNTech have any subsidiaries? The following companies are subsidiaries of BioNTech: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, and more. When did BioNTech IPO? BioNTech (BNTX) raised $155 million in an initial public offering (IPO) on Thursday, October 10th 2019. The company issued 10,000,000 shares at $15.00-$16.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink acted as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers. Who are BioNTech's major shareholders? BioNTech's top institutional shareholders include Dodge & Cox (1.46%), First Trust Advisors LP (0.39%), Assenagon Asset Management S.A. (0.30%) and GSK plc (0.26%). Insiders that own company stock include Sierk Poetting and Ugur Sahin. View institutional ownership trends. How do I buy shares of BioNTech? Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioNTech own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioNTech investors own include Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Pfizer (PFE), Advanced Micro Devices (AMD), Novavax (NVAX) and NIO (NIO). Company Calendar Last Earnings8/04/2026Today11/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 BNTX's financial health is in the Yellow zone, according to TradeSmith. BNTX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BNTX CIK1776985 Webwww.biontech.com Phone49-61-31908-40Fax49-6131-908-4390Employees7,807Year Founded2008Price Target and Rating Average Price Target for BioNTech$120.44 High Price Target$155.00 Low Price Target$93.00 Potential Upside/Downside+49.1%Consensus RatingModerate Buy Rating Score (0-4)2.65 Research Coverage20 Analysts Profitability EPS (Trailing Twelve Months)($6.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.29 billion Net Margins-61.39% Pretax Margin-60.67% Return on Equity-4.51% Return on Assets-3.96% Debt Debt-to-Equity Ratio0.01 Current Ratio8.55 Quick Ratio8.52 Sales & Book Value Annual Sales$2.42 billion Price / Sales8.44 Cash Flow$1.33 per share Price / Cash Flow60.64 Book Value$80.61 per share Price / Book1.00Miscellaneous Outstanding Shares252,884,000Free Float204,330,000Market Cap$20.43 billion OptionableOptionable Beta1.28 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:BNTX) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredA quick test most investors failCan you defend your biggest holding? Seeking Alpha Premium gives you its Quant valuation grade versus its sect...Seeking Alpha | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNTech SE Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share BioNTech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.